Education
About Us
Working with TipRanks
Follow Us
EnBio Holdings, Inc. (JP:6092)
:6092
6092 Stock Chart & Stats
¥598.00
-¥2.00(-0.33%)
At close: 4:00 PM EST
¥598.00
-¥2.00(-0.33%)
Day’s Range― - ―
52-Week Range¥500.00 - ¥746.00
Previous CloseN/A
Volume5.80K
Average Volume (3M)25.91K
Market Cap
¥5.25B
Enterprise Value¥11.82B
Total Cash (Recent Filing)¥3.19B
Total Debt (Recent Filing)¥10.28B
Price to Earnings (P/E)―
Beta0.63
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.54%
Share Statistics
EPS (TTM)-75.25
Shares Outstanding8,175,200
10 Day Avg. Volume21,320
30 Day Avg. Volume25,910
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)0.53
Price to Sales (P/S)0.45
P/FCF Ratio-3.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthDouble-digit revenue growth year-over-year demonstrates durable demand and underlying business momentum. Sustained top-line expansion supports economies of scale, improves the ability to fund R&D and strategic initiatives, and provides a foundation for long-term margin improvement and reinvestment.
Healthy Operating MarginsRobust EBITDA and gross margins indicate efficient operations and reasonable pricing power within its specialty services niche. A durable margin profile helps the firm absorb cost shocks, finance growth without immediate dilution, and sustain profitability as the business scales over months to years.
Balanced Capital StructureModerate leverage and a solid equity ratio give EnBio financial flexibility to fund strategic investments and capex without excessive refinancing risk. A balanced capital structure supports stable operations, enables opportunistic growth spending, and reduces vulnerability to cyclical funding stresses.
Bears Say
Negative Free Cash FlowFCF turning negative due to elevated capex indicates investments currently outpace cash generation. If capex does not translate to higher returns quickly, persistent negative FCF can force external financing, constrain strategic options, and pressure liquidity over the medium term.
Poor Cash ConversionAn OCF-to-net-income ratio near 0.05 signals weak cash conversion and potential earnings quality issues. Low conversion reduces the firm's ability to self-fund growth, service debt, or return capital to shareholders, making operating results less reliable as a base for long-term planning.
Severe EPS DeclineA dramatic EPS contraction indicates volatile profitability and challenges turning revenue into per-share earnings. Large negative EPS growth undermines investor confidence in management's capital allocation and suggests operational or non-recurring hits that could limit reinvestment and shareholder value creation.
EnBio Holdings, Inc. News
6092 FAQ
What was EnBio Holdings, Inc.’s price range in the past 12 months?
EnBio Holdings, Inc. lowest stock price was ¥500.00 and its highest was ¥746.00 in the past 12 months.
What is EnBio Holdings, Inc.’s market cap?
EnBio Holdings, Inc.’s market cap is ¥5.25B.
When is EnBio Holdings, Inc.’s upcoming earnings report date?
EnBio Holdings, Inc.’s upcoming earnings report date is May 20, 2026 which is in 86 days.
How were EnBio Holdings, Inc.’s earnings last quarter?
EnBio Holdings, Inc. released its earnings results on Feb 13, 2026. The company reported -¥75.25 earnings per share for the quarter, missing the consensus estimate of N/A by -¥75.25.
Is EnBio Holdings, Inc. overvalued?
According to Wall Street analysts EnBio Holdings, Inc.’s price is currently Overvalued.
Does EnBio Holdings, Inc. pay dividends?
EnBio Holdings, Inc. pays a Annually dividend of ¥9 which represents an annual dividend yield of 1.54%. See more information on EnBio Holdings, Inc. dividends here
What is EnBio Holdings, Inc.’s EPS estimate?
EnBio Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EnBio Holdings, Inc. have?
EnBio Holdings, Inc. has 8,175,200 shares outstanding.
What happened to EnBio Holdings, Inc.’s price movement after its last earnings report?
EnBio Holdings, Inc. reported an EPS of -¥75.25 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.165%.
Which hedge fund is a major shareholder of EnBio Holdings, Inc.?
Currently, no hedge funds are holding shares in JP:6092
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
EnBio Holdings, Inc.
EnBio Holdings Co., Ltd. engages in soil and groundwater contamination, and renewable energy businesses in Japan. It imports and sells equipment, materials, and cleaning agents; and purchases, sells, and leases contaminated land. The company is also involved in solar power; biomass power generation; renewable energy power generation; water resource development; and ethical consumption promotion businesses. EnBio Holdings Co., Ltd. was incorporated in 1999 and is headquartered in Tokyo, Japan.
Technical Analysis
Hikari Business Form Co., Ltd.
―
CRESTEC Inc.
―
Sougou Shouken Co., Ltd.
―
Sun Messe Co., Ltd.
―
Mitsumura Printing Co., Ltd.
―